Heron Therapeutics, INC. /De/ (HRTX) — DEF 14A Filings

All DEF 14A filings from Heron Therapeutics, INC. /De/. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.

DEF 14A Filings (3)

Heron Therapeutics Seeks Shareholder Nod for Key Stock Issuances — Sep 19, 2025 Risk: medium
Heron Therapeutics, Inc. (HRTX) is seeking stockholder approval for two proposals related to the issuance of common stock that could exceed 19.99% of its outsta
Heron Therapeutics Executive Compensation Details Released — Apr 30, 2025 Risk: medium
Heron Therapeutics, Inc. filed a DEF 14A on April 30, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes i
Heron Therapeutics Announces 2024 Annual Meeting of Stockholders on June 13, 2024 — Apr 29, 2024 Risk: medium
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Heron Therapeutics will hold its 2024 Annual Meeting of S

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX